Good Morning Weather very nice in Portugal - Diagnostics getting on with the day job - Therapeutics still in preparation for take- off : SP watchers looking for pennies - shareholders just sit back & relax .
------------------
Note : Coris/LD working together
Launch Diagnostics France SASLaunch Diagnostics France SAS
216 followers216 followers
2d • 2d •
Follow
Launch Diagnostics France SAS : Distributeur exclusif des produits de la gamme RESIST de Coris Bioconcept en France
hashtag#antibioresistance hashtag#AMR hashtag#RESIST hashtag#BMR hashtag#Testsrapides
Rate this translation
Launch Diagnostics France SAS: Exclusive distributor of Coris Bioconcept's RESIST range products in France
hashtag#antibioresistance hashtag#AMR hashtag#RESIST hashtag#BMR hashtag#Testsrapides
-----------
LD man in Germany getting to know the team
"Lena KastlLena Kastl
• 3rd+• 3rd+
Managing Director bei Launch Diagnostics Deutschland GmbHManaging Director bei Launch Diagnostics Deutschland GmbH
4d • 4d •
Follow
Get in touch and meet newly established Launch Diagnostics Deutschland GmbH at ECCMID in Barcelona!
https://www.linkedin.com/in/davidswilson/recent-activity/all/
Not a very cheery board today . I prefer to concentrate on the positives . .
Avacta managenent great foresight to obtain control of the science technology & hold the IP licences . As has been ably demonstrated recently in presentations the science works . Will eventually deliver substantial investment returns . Then the same folks bad mouthing the managenent today will then be singing their praises and we will all be very happy .
"Avacta commenced a two-weekly dosing safety study in the US on the basis that this is likely to lead to better efficacy. Three patients have now been dosed in cohort 1 (160 mg/m2) of the two-weekly dose escalation study in the US and Avacta has received regulatory and ethics approval to open sites in the UK in the two-weekly arm. Avacta anticipates that the SMDC will review the two-weekly cohort 1 data by the end of April."
"A company’s IP strategy should manage and protect its intellectual property in a way that aligns with its overall business goals and strategy, ensuring that the intellectual property is being effectively protected, optimized (for value), and monetized (when possible), maximizing the value of the protected assets and their potential commercial benefits.
https://www.excedr.com/resources/intellectual-property-strategy-for-biotechs
Note :
"CORIS BIOCONCEPTCORIS BIOCONCEPT
2,555 followers2,555 followers
3d • 3d •
Follow
𝗘𝗖𝗖𝗠𝗜𝗗 𝟮𝟬𝟮𝟰 is approaching fast! 🚀
The congress will be held this year in the wonderful city of Barcelona 🇪🇸 from April 27th to 30th. We can't wait to be there!
Come and meet us at booth F-10 to discuss rapid tests and AntiMicrobial Resistance. 🦠🧫
https://www.eccmid.org/#
Visit our website for more information: https://www.corisbio.com
Fight #AMR together
#ECCMID2024 #Innovation #RapidTests #GlobalHealth #RaiseAwareness"
Whatever the logic , it would make sense for Avacta diagnostics to be a going cencern might help the future sale proceeds .
Coris purchase
Dr Alastair Smith, Chief Executive Officer, Avacta Group plc, commented:
“The acquisition of Coris provides the Group with a broad, professional-use rapid test product portfolio. Complementing the acquisition of Launch Diagnostics last year, the Acquisition represents an important step in establishing a full-spectrum in-vitro diagnostics business covering centralised, pathology laboratory diagnostics, as well as decentralised, point-of-care testing solutions outside the hospital setting.
“Antibiotic resistance is a major global challenge and we strongly believe that the market for antimicrobial resistance (“AMR”) testing is one with good future growth prospects. We are particularly pleased, therefore, to have added an AMR product portfolio to the Group with this acquisition.
“With this acquisition, our Diagnostics division has taken another important step towards realising its mission to support healthcare professionals and broaden access to high quality diagnostics.”
--------------
"The global antimicrobial resistance diagnostics market size was valued at USD 3.9 billion in 2021 and is expected to expand at a compound annual growth rate (CAGR) of 6.2% from 2022 to 2030. High disease burden from pathogens such as streptococcus pneumonia, MRSA, C. difficile infections, and others coupled with the surge in the incidence of Antimicrobial Resistance (AMR) infections are the major factors fueling the market growth."
LD distribute products for 40 + manufacturers - profitable business aquisition for the Avacta Group , be interesting to see the next accounts .
--------------------------------------
https://en.vircell.com/
https://www.launchdiagnostics.com/
---------------------
Launch Diagnostics LimitedLaunch Diagnostics Limited
1,558 followers1,558 followers
1d • 1d •
Ensuring Quality in Molecular Testing: Introducing Vircell's Amplirun and Amplirun Total Ranges
Quality assurance is the cornerstone of every testing laboratory, and third-party molecular controls play a key role in this process. Vircell's Amplirun and Amplirun Total ranges offer comprehensive solutions for various applications:
🔹 Amplirun: With over 140 single-target controls, Amplirun is perfect for daily use, enabling precise determination of parameters like Limit of Detection (LoD). Plus, with concentrations ranging from 12500 to 20000 copies/µl, accuracy is guaranteed.
🔹 Amplirun Total: Featuring 20 full-process molecular controls, Amplirun Total sets the standard with clinically appropriate matrices that mimic human samples. These controls are multiplexed for an efficient Quality Control (QC) workflow.
Whether it's routine daily testing, batch acceptance, or assay verification, Vircell's solutions provide the reliability and accuracy labs need. Elevate your laboratory's quality assurance with Amplirun and Amplirun Total from Vircell.
https://lnkd.in/e2UMvkF4
https://lnkd.in/enyyBKZj
---------
P.S. Thankfully @ beinthelead has me blocked so will not be having a meltdown .
Courtesy of @Ophidian18 twitter ; Thought this worth sharing - Avacta science offers something different "No other system is whole Tumour targeting"
-----------------------------------
"I want to just unpick something which #AVCT have said a couple of times recently both CC and last night AS as I'm not sure it has really landed for everyone.
And that is around the Peptide Drug Conjugate platform (pre|CISION) being the ONLY system that targets the Tumour
9:41 AM · Apr 11, 2024
·
1,258
Views
Replying to @Ophidian18
No file chosen
Ophidian
@Ophidian18
·
1h
Sure there are now more than a dozen registered ADCs (and dozens more in development) that target a specific antigen, but that antigen is usually ONLY present on a specific cell type - typically the cancer cell and that is NOT the Tumour the Tumour is unfortunately much more.
Ophidian
@Ophidian18
·
1h
FAP is expressed in CAFs as well as on the cell surface of some cancerous cells. Because the Peptide Drug Conjugate system is cleaved rather than binding that means that through the bystander effect, pre|CISION provides a mechanism to target the whole Tumour
Ophidian
@Ophidian18
·
1h
As well as providing a highly specific and discriminating way to deliver a cytotoxic warhead to the Tumour the PDC could also land an ADC to specifically target cancerous cells right in the Tumour where it is needed sparing other tissues. No other system is whole Tumour targeting"
good morning appreciate dr smith taking the time to explain the science and give thoughtful answers .
for those that continue to **** off company management that is of course your prerogative . will not change anything as frankly zero chance the founder of the company will be removed .
dr smith has the ip under control , no doubt in my mind shareholders will eventually be rewarded . obviously not as quick as some of you expected sorry about that . anyway we start again. better in my view stick with the science & support the avacta team & take responsibility for your own investment decisions .
have a nice day .
Avacta well funded , can now continue with clinical plans , no reason to think they will not succeed . Quite exceptional for Avacta to have presented such comprehensive data for a partially completed phase one trial. Visible evidence that the POC technology treatment works . Super safety & amazing signs of early efficancy which is tremedous news for those pre-treated patients . Going forward . Looks like more frequent two weekly dosing will provide better cumulative exposure for efficancy not a single max dose. So not long before those results then ready for phase 2 next stage . Re-Rate .
Avacta already have a major pharma :Lilly have a licence (Point B ) " The agreement provides POINT with an exclusive license to the pre|CISION technology for use in the first radiopharmaceutical prodrug the company intends to develop, and a non-exclusive license to the pre|CISION™ platform for the development of a broader pipeline of FAP-activated radiopharmaceuticals."
We wait & see who else decides to get involved , many other cancer drugs could be added , means more licences + opportunity to provide ADC comparable treatments - huge global market awaits .
Plus Avacta have other JV assets & diagnostics . Anyway one thing for sure certainly a marathon not a sprint for all parties involved . Look forward to the day ( -current paper deficit -53.31% --- the other way around .)
Good luck everyone
Capital Markets -just for AVA6000
"The results confirm the positive progress being made in the clinical testing of AVA6000 and support the company’s above target fundraise of £31.1m completed in March which will fund the dose expansion and Phase 2 efficacy studies for AVA6000 as well as progress the company’s drug pipeline more generally, including its AVA3996 asset. If Phase 2 testing enables commercial sales to start from 2026/27, we calculate a value for AVA6000 alone at 89p rising to 182p on the implementation of Phase 2 testing. "
https://avacta.com/investors/research-analyst
Thanks : https://twitter.com/udai_banerji/status/1777778199289581619
udaibanerji
@udai_banerji
New frontiers in exploiting stroma for therapy. FAP directed precision medicine. Phase I of AVA600 showing tolerability, plasmas/tumour PK and clinical proof of concept response in FAP high tumours. Abstract CT188 #AACR2024
@ICR_London
@royalmarsdenNHS
@ECMC_UK
Not quite the stampede yet but business discussions always in private .
"If you are attending #AACR24 stop by to see our poster presentation today 9:00 AM – 12:30 PM (PDT)."
https://twitter.com/avacta/status/1777731660416524727
FYI ; CC explains https://avacta.wistia.com/medias/b74537ezmn
Https://avacta.com/wp-content/uploads/2024/04/Banerji-et-al-2024-AVA6000-AACR_final.pdf
AACR -ADC sessions very busy :
Apparently "Easier to get a ticket for a Taylor Swift concert than to find a seat at the #AACR24 Next Generation ADC session!" wait to they hear about : https://avacta.com/precision/precision-drug-conjugate-pdc/
"https://twitter.com/PTarantinoMD/status/1777071782010474563/photo/1
Note :
"Launch Diagnostics LimitedLaunch Diagnostics Limited
1,545 followers1,545 followers
4h • 4h •
At Launch Diagnostics, we're committed to providing innovative diagnostic solutions in a sustainable way. Here's how we're taking actionable steps towards sustainability:
• An eco-friendly fleet of hybrid and electric vehicles for our field-based staff.
• Dramatic plastic reduction in our packaging using alternatives wherever possible.
• Our office move means our headquarters are now more energy efficient.
• Working with sustainable partners helps us ensure that our work is as green as possible at each step of the logistics chain.
• Reduction and monitoring our paper usage allows us to minimise our environmental footprint.
Sustainability is our guiding principle that shapes everything we do. Together, we're pioneering solutions that advance healthcare and preserve the environment.
What is your organisation doing for a more sustainable future?
https://www.linkedin.com/feed/update/urn:li:activity:7183377567540781057/
While we wait for the big poster reveal my expectation - is the Avacta CBO standing in the wings saying please form an orderly queue to a stampede of biotech executives clambering to get a pre|CISIONTM stake with open cheque books.
Fingers crossed .
Diagnostics is anathema to some here . Home page quite rightly promoting "pre|CISIONTM
Concentrating highly potent warheads in the tumour microenvironment "-----------however if someone new looking at the Avacta website for the first time they would probably like to see what Avacta was all about .
https://avacta.com/about/
"About Avacta
Avacta Group is a UK-based life sciences company focused on improving healthcare outcomes through targeted cancer treatments and diagnostics." so diagnostics not exactly being ignored .
No need for guesswork - SDMC very happy to proceed with the clinical trial & test new protocols .
"Cohort 7 was the final cohort in the three-weekly study and even at this dose level (385 mg/m2), which is approximately 3.5x the equivalent standard dose of doxorubicin, dose-limiting toxicities were not observed and the Safety Data Monitoring Committee ("SMDC") has concluded that this dose level is safe. A number of patients remain on the three-weekly study at this time in several different cohorts.
Based on this very favourable three-weekly dosing safety profile, Avacta commenced a two-weekly dosing safety study in the US on the basis that this is likely to lead to better efficacy. Three patients have now been dosed in cohort 1 (160 mg/m2) of the two-weekly dose escalation study in the US and Avacta has received regulatory and ethics approval to open sites in the UK in the two-weekly arm. Avacta anticipates that the SMDC will review the two-weekly cohort 1 data by the end of April."